Cargando…

Analysis of the Fibroblast Growth Factor System Reveals Alterations in a Mouse Model of Spinal Muscular Atrophy

The monogenetic disease Spinal Muscular Atrophy (SMA) is characterized by a progressive loss of motoneurons leading to muscle weakness and atrophy due to severe reduction of the Survival of Motoneuron (SMN) protein. Several models of SMA show deficits in neurite outgrowth and maintenance of neuromus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hensel, Niko, Ratzka, Andreas, Brinkmann, Hella, Klimaschewski, Lars, Grothe, Claudia, Claus, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278439/ https://www.ncbi.nlm.nih.gov/pubmed/22348054 http://dx.doi.org/10.1371/journal.pone.0031202

Ejemplares similares

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy
por: Spicer, Charlotte, et al.
Publicado: (2021)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Fibroblast Growth Factor Signalling in the Diseased Nervous System
por: Klimaschewski, Lars, et al.
Publicado: (2021)

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
por: Sleigh, James N., et al.
Publicado: (2011)

Increased susceptibility of spinal muscular atrophy fibroblasts to camptothecin is p53-independent
por: Wu, Chia-Yen, et al.
Publicado: (2009)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN
por: Rademacher, Sebastian, et al.
Publicado: (2020)

Differential induction of muscle atrophy pathways in two mouse models of spinal muscular atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2016)

The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
por: Feng, Yijie, et al.
Publicado: (2023)

Regulation of Neuronal Differentiation by Proteins Associated with Nuclear Bodies
por: Förthmann, Benjamin, et al.
Publicado: (2013)

Modeling the phenotype of spinal muscular atrophy by the direct conversion of human fibroblasts to motor neurons
por: Zhang, Qi-Jie, et al.
Publicado: (2017)

Synaptic Defects in the Spinal and Neuromuscular Circuitry in a Mouse Model of Spinal Muscular Atrophy
por: Ling, Karen K. Y., et al.
Publicado: (2010)

The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap
por: Brown, Sharon J., et al.
Publicado: (2022)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Sm-like proteins in the pathogenesis of Spinal Muscular Atrophy
por: Achsel, Tilmann, et al.
Publicado: (2015)

Systemic nature of spinal muscular atrophy revealed by studying insurance claims
por: Lipnick, Scott L., et al.
Publicado: (2019)

FGF-2 Deficiency Does Not Influence FGF Ligand and Receptor Expression during Development of the Nigrostriatal System
por: Ratzka, Andreas, et al.
Publicado: (2011)

In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy
por: Ojala, Kristine S., et al.
Publicado: (2021)

The alteration of left ventricular strain in later-onset spinal muscular atrophy children
por: Cui, Yiqin, et al.
Publicado: (2022)

R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy
por: Tejero, Rocio, et al.
Publicado: (2020)

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
por: Lusakowska, Anna, et al.
Publicado: (2021)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Mitochondrial abnormalities in spinal and bulbar muscular atrophy
por: Ranganathan, Srikanth, et al.
Publicado: (2009)

Rapid molecular diagnosis of spinal muscular atrophy
por: Mittal, Balraj
Publicado: (2012)

Cardiac involvement in patients with Spinal Muscular Atrophies
por: Palladino, Alberto, et al.
Publicado: (2011)

Clinical features of spinal and bulbar muscular atrophy
por: Rhodes, Lindsay E., et al.
Publicado: (2009)

Disease burden of spinal muscular atrophy in Germany
por: Klug, Constanze, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rh2digmu3bhpiqvf7togup769v